Literature DB >> 31862752

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

.   

Abstract

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
© 2019 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31862752     DOI: 10.2337/dc20-S009

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  242 in total

Review 1.  Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.

Authors:  Tanya Wilcox; Christophe De Block; Arthur Z Schwartzbard; Jonathan D Newman
Journal:  J Am Coll Cardiol       Date:  2020-04-28       Impact factor: 24.094

2.  Beneficial Agents for Patients With Type 2 Diabetes and Cardiovascular Disease or Obesity: Utilization in an Era of Accumulating Evidence.

Authors:  Kelsey Buckley; Kathleen A Fairman
Journal:  Clin Diabetes       Date:  2020-04

3.  Improving Equity in Medication Use through Better Kidney Function Measurement.

Authors:  Delphine S Tuot
Journal:  J Am Soc Nephrol       Date:  2020-07-13       Impact factor: 10.121

4.  Low-Carbohydrate and Very-Low-Carbohydrate Diets in Patients With Diabetes.

Authors:  Jennifer D Merrill; Diana Soliman; Nitya Kumar; Sooyoung Lim; Afreen I Shariff; William S Yancy
Journal:  Diabetes Spectr       Date:  2020-05

5.  Use of Premixed Insulin, Metformin, and a Glucagon-Like Peptide 1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes.

Authors:  Nicole Ehrhardt; Sasan Fazeli; Sanjana Rao; Richard Amdur
Journal:  Diabetes Spectr       Date:  2020-05

6.  Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes.

Authors:  John E Anderson
Journal:  Diabetes Spectr       Date:  2020-05

7.  Sitagliptin-Induced Arthralgias: A Case Report.

Authors:  Raven Jackson; Isabel Sbeiti; Gabrielle Vincent
Journal:  Clin Diabetes       Date:  2020-07

Review 8.  Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.

Authors:  Kevin Cowart
Journal:  Clin Diabetes       Date:  2020-07

Review 9.  Remogliflozin: the new low cost SGLT-2 inhibitor for type 2 diabetes mellitus.

Authors:  Shubham Atal; Zeenat Fatima; Sakshi Singh; Sadasivam Balakrishnan; Rajnish Joshi
Journal:  Diabetol Int       Date:  2020-10-29

Review 10.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.